Unknown

Dataset Information

0

A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy


ABSTRACT: Immune checkpoint blockade (ICB) therapies that target programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway are currently used for the treatment of various cancer types. However, low response rates of ICB remain the major issue and limit their applications in clinic. Here, we developed a ROS-responsive synergistic delivery system (pep-PAPM@PTX) by integrating physically-encapsulated paclitaxel (PTX) and surface-modified anti-PD-L1 peptide (pep) for combined chemotherapy and ICB therapy. Pep-PAPM@PTX could bind the cell surface PD-L1 and drive its recycling to lysosomal degradation, thus reverting PTX-induced PD-L1 upregulation and downregulating PD-L1 expression. As a result, pep-PAPM@PTX significantly promoted T cell infiltration and increased tumor immunoactivating factors, synergizing PTX chemotherapy to achieve enhanced anticancer potency in a triple-negative breast cancer (TNBC) model. Graphical abstract A ROS-responsive synergistic delivery system (pep-PAPM@PTX) was developed by integrating physically-encapsulated paclitaxel (PTX) and surface-modified anti-PD-L1 peptide (pep) for combined chemotherapy and ICB therapy.Image 1

SUBMITTER: Hu D 

PROVIDER: S-EPMC9130108 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC11394823 | biostudies-literature
| S-EPMC7770705 | biostudies-literature
| S-EPMC6382314 | biostudies-literature
| S-EPMC7473403 | biostudies-literature
| S-EPMC6712559 | biostudies-literature
| S-EPMC9823741 | biostudies-literature
| S-EPMC7019163 | biostudies-literature
| S-EPMC10018933 | biostudies-literature
| S-EPMC10013198 | biostudies-literature
| S-EPMC11754682 | biostudies-literature